[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

April 2020 - April 2015

Decade

Year

Issue

April 2020, Vol 6, No. 4, Pages 456-596

Original Investigation

Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study

Abstract Full Text
JAMA Oncol. 2020;6(4):486-493. doi:10.1001/jamaoncol.2019.5140

This nonrandomized clinical trial examines the association of age with survival among Medicare beneficiaries with myelodysplastic syndrome who underwent allogeneic hematopoietic stem cell transplantation.

Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma

Abstract Full Text
JAMA Oncol. 2020;6(4):495-503. doi:10.1001/jamaoncol.2019.6143

This multicenter cohort study assesses the association of maximal extent of resection of contrast-enhanced and non–contrast-enhanced tumor with survival among patients with newly diagnosed glioblastoma in different molecular subgroups to develop a new road map for cytoreductive surgery.

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(4):505-511. doi:10.1001/jamaoncol.2019.5559

This cohort study examines the association between recurrence score and locoregional recurrence in postmenopausal women who received treatment for node-positive, estrogen receptor– or progesterone receptor–positive breast cancer.

Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer

Abstract Full Text
has audio
JAMA Oncol. 2020;6(4):512-518. doi:10.1001/jamaoncol.2019.5241

This cohort study examines the association between body mass index and survival in patients with non–small cell lung cancer who receive immune checkpoint inhibitor therapy.

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2020;6(4):519-527. doi:10.1001/jamaoncol.2019.5570

This secondary analysis of a randomized clinical trial examines the association between immune-related adverse events and recurrence-free survival among patients with high-risk stage III melanoma who were treated with pembrozimulab therapy or placebo in the EORTC 1325/KEYNOTE-054 study.

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(4):528-534. doi:10.1001/jamaoncol.2019.6276

This secondary analysis of a randomized clinical trial examines 20-year efficacy and safety outcomes of a large trial of adjuvant high-dose chemotherapy and hematopoietic stem cell transplant (HSCT) vs conventional-dose chemotherapy for patients with stage III breast cancer.

Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(4):535-541. doi:10.1001/jamaoncol.2019.6584

This nonrandomized phase 1/2 clinical trial evaluates the use of trabectedin in combination with low-dose radiotherapy for treating metastatic soft-tissue sarcomas in adult patients.

Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer

Abstract Full Text
online only
JAMA Oncol. 2020;6(4):e196400. doi:10.1001/jamaoncol.2019.6400

This population-based cohort study examines the association of germline genetic testing results with locoregional and systemic therapy use in women aged 20 years or older diagnosed with breast cancer.

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer

Abstract Full Text
online only has audio
JAMA Oncol. 2020;6(4):e196496. doi:10.1001/jamaoncol.2019.6496

This study examines the development and outcomes of men with the HSD3B1 genotype receiving treatment for metastatic prostate cancer.

Brief Report

Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status

Abstract Full Text
JAMA Oncol. 2020;6(4):542-546. doi:10.1001/jamaoncol.2019.6390

This cohort study compares health care expenditures of patients with chronic myeloid leukemia for first- and second-generation tyrosine kinase inhibitors before and after the transition of imatinib to generic status.

Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(4):547-551. doi:10.1001/jamaoncol.2019.6486

This open-label, multicenter, phase 3 trial conducted in Italy assesses 5-year relapse-free survival to evaluate the noninferiority of 3 months (experimental arm) vs 6 months (control arm) of standard doses of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) adjuvant chemotherapy in patients with high-risk stage II resected colorectal cancer enrolled in the TOSCA trial.

Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer

Abstract Full Text
open access
JAMA Oncol. 2020;6(4):552-556. doi:10.1001/jamaoncol.2019.4120

This pilot cohort study estimates sensitivity and specificity of plasma microbial cell-free DNA sequencing for its ability to predict bloodstream infection in patients at high risk of life-threatening infection.

Research Letter

Random vs Targeted Urine Drug Testing Among Patients Undergoing Long-term Opioid Treatment for Cancer Pain

Abstract Full Text
JAMA Oncol. 2020;6(4):580-581. doi:10.1001/jamaoncol.2019.6756

This cohort study assesses the frequency of abnormal urine drug test findings among patients with cancer pain treated with long-term opioid therapy who underwent random and targeted testing.

Review

Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(4):567-577. doi:10.1001/jamaoncol.2019.5351

This review of stereotactic ablative radiotherapy for spinal metastases contextualizes decisions about optimal multidisciplinary management to help clinicians provide personalized high-quality care for these patients.

JAMA Oncology Clinical Challenge

Erythematous Patch With Central Papules on the Forehead of a Middle-aged Woman

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(4):578-579. doi:10.1001/jamaoncol.2019.6289

A middle-aged woman presented with a tender, pruritic, 4-cm erythematous patch on the forehead that enlarged over the course of 6 weeks. What is your diagnosis?

Viewpoint

An Action Plan for Environmentally Sustainable Cancer Care

Abstract Full Text
JAMA Oncol. 2020;6(4):469-470. doi:10.1001/jamaoncol.2019.5364

This Viewpoint exposes the need for environmentally sustainable oncology practices and facilities and evaluates strategies for achieving both.

Will Medical Preprints Change Oncology Practice?

Abstract Full Text
JAMA Oncol. 2020;6(4):471-472. doi:10.1001/jamaoncol.2019.5972

This Viewpoint discusses limitations of preprints and how they may change oncology practice and research.

New Graphic Tobacco Warnings and the First Amendment

Abstract Full Text
JAMA Oncol. 2020;6(4):473-474. doi:10.1001/jamaoncol.2019.5975

This Viewpoint descibes a new proposed US Food and Drug Administration rule that would require graphic warnings for cigarette packages and advertisements and discusses the legality of the rule compared with a previous attempt to implement a similar set of graphic warnings on these products.

Invited Commentary

Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?Considering the Results of the Medicare Coverage With Evidence Development Study

Abstract Full Text
JAMA Oncol. 2020;6(4):493-494. doi:10.1001/jamaoncol.2019.5135

A Common Rule for Resection of Glioblastoma in the Molecular Era

Abstract Full Text
JAMA Oncol. 2020;6(4):503-504. doi:10.1001/jamaoncol.2019.6384
JAMA Oncology Patient Page

Brachytherapy

Abstract Full Text
free access
JAMA Oncol. 2020;6(4):596. doi:10.1001/jamaoncol.2019.5882

This Patient Page describes the use of brachytherapy (internal radiation) for the treatment of cancer and its delivery, adverse effects, and indications.

Cancer Care Chronicles

First Rites—A Spiritual History Case Study

Abstract Full Text
JAMA Oncol. 2020;6(4):475-476. doi:10.1001/jamaoncol.2019.5980

This article describes an oncologist’s experience engaging in the spiritual lives of a patient with terminal illness and her family.

Poetry and Oncology

Medicine Is Not a Subway Ride

Abstract Full Text
JAMA Oncol. 2020;6(4):591. doi:10.1001/jamaoncol.2019.6745
Comment & Response

Variant Interpretation in Patients With Metastatic Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(4):581-582. doi:10.1001/jamaoncol.2019.6397

Variant Interpretation in Patients With Metastatic Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(4):582-583. doi:10.1001/jamaoncol.2019.6409

Using Real-world Historical Controls to Evaluate Radiation Dose Escalation in Esophageal Cancer

Abstract Full Text
JAMA Oncol. 2020;6(4):583. doi:10.1001/jamaoncol.2019.6406

Using Real-World Historical Controls to Evaluate Radiation Dose Escalation in Esophageal Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(4):583-584. doi:10.1001/jamaoncol.2019.6412

Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(4):584-585. doi:10.1001/jamaoncol.2019.6706

Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(4):585-586. doi:10.1001/jamaoncol.2019.6709

Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(4):586. doi:10.1001/jamaoncol.2019.6712

Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Abstract Full Text
JAMA Oncol. 2020;6(4):586-587. doi:10.1001/jamaoncol.2019.6859

Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Abstract Full Text
JAMA Oncol. 2020;6(4):587. doi:10.1001/jamaoncol.2019.6865

Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(4):587-588. doi:10.1001/jamaoncol.2019.6868

Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes

Abstract Full Text
JAMA Oncol. 2020;6(4):588-589. doi:10.1001/jamaoncol.2020.0056

Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes

Abstract Full Text
JAMA Oncol. 2020;6(4):589-590. doi:10.1001/jamaoncol.2020.0065

Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes—Reply

Abstract Full Text
JAMA Oncol. 2020;6(4):590. doi:10.1001/jamaoncol.2020.0068
Correction

Status Change to Open Access After Publication

Abstract Full Text
free access
JAMA Oncol. 2020;6(4):590. doi:10.1001/jamaoncol.2020.0176
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2020;6(4):456. doi:10.1001/jamaoncol.2019.4215
×